期刊文献+

1997-2008年全国传染病监测系统报告的肺结核发病情况分析 被引量:27

Incidence of pulmonary tuberculosis reported by national notifiable communicable diseases surveillance system,1997-2008
原文传递
导出
摘要 目的了解全国传染病监测系统报告肺结核发病特征。方法收集1997-2008年传染病监测系统报告的肺结核疫情资料进行了描述性和比较性分析。结果全国肺结核报告发病率总体呈上升趋势,其中1997-2002年上升缓慢,2003年之后上升明显,2005年达到高峰,目前仍保持在较高水平。季节性分布不明显,以经济欠发达的西部和中部为主,男性高于女性,15~45岁年龄组报告发病所占比例较高。结论中国结核病疫情仍然很严重,应该作为重点传染病加强各项防控措施,切实提高现代结核病控制工作策略的质量。 Objective To understand the incidence characteristics of pulmonary tuberculosis (TB) reported by national notifiable communicable diseases surveillance system. Methods The data of pulmonary TB epidemic reported by national notifiable communicable diseases surveillance system from 1997 to 2008 were collected to conduct descriptive analysis and comparison. Results the overall incidence of pulmonary TB increased with a slight increase during 1997- 2002, obvious increase after 2003 and peak in 2005, the incidence to date still remained high. The incidence of pulmonary TB had no obvious seasonality. The disease mainly distributed in less developed western and central regions. There were more male cases than female cases. The reported cases in people aged 15 - 45 years accounted for larger proportion. Conclusion The TB epidemic is still serious in China, it is necessary to strengthen the TB prevention and control as a priority disease and practically improve the quality of modern TB control.
出处 《疾病监测》 CAS 2009年第11期878-881,共4页 Disease Surveillance
关键词 肺结核 发病 分析 tuberculosis incidence analysis
  • 相关文献

参考文献4

二级参考文献33

  • 1Onyebujoh P,Rook GA. Tuberculosis. Nat Rev Microbiol,2004,2 : 930-932.
  • 2Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet, 1995,346 : 1339 -1345.
  • 3Orme IM. Current progress in tuberculosis vaccine development. Vaccine,2005:23 : 2105-2108.
  • 4Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol,2001,1:20-30.
  • 5Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol,2005 ,26 :660-667.
  • 6Hawgood BJ. Doctor Albert Calmette 1863-1933: founder of antivenomous serotherapy and of antitubereulosis BCG vaccination. Toxicon, 1999,37 : 1241-1258.
  • 7Soysal A, Millington KA,Bakir M,et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet ,2005,366 : 1443-1451.
  • 8Andersen P, Doherty TM. The success and failure of BCG- implications for a novel tuberculosis vaccine. Nat Rev Microbiol, 2005,3:656-662.
  • 9Behr MA, Wilson MA, Gill WP, et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science, 1999, 284 : 1520-1523.
  • 10Okkels LM, Doherty TM, Andersen P. Selecting the components for a safe and efficient tuberculosis subunit vaccine-recent progress and post-genomic insights. Curt Pharm Biotechnol, 2003,4 : 69- 83.

共引文献159

同被引文献126

引证文献27

二级引证文献134

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部